Biological therapies in the systemic management of psoriasis: International Consensus Conference

British Journal of Dermatology, Supplement

Volumn 151, Issue 69, 2004, Pages 3-17

  Sterry, Wolfram ^a   Barker, J ^b   Boehncke, W H ^c   Bos, J D ^d   Chimenti, S ^e   Christophers, E ^f   De La Brassinne, M ^g,i   Ferrandiz, C ^h   Griffiths, C ^w   Katsambas, A ^j   Kragballe, K ^k   Lynde, C ^l   Menter, A ^m   Ortonne, J P ⁿ   Papp, K ^o   Prinz, J ^p   Rzany, B ^a   Ronnevig, J ^q   Saurat, J H ^r   Stahle, M ^s   Stengel, F M ^t   Van De Kerkhohf, P ^u   Voorhees, J ^v   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF KIEL   (Germany)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l Lynde Centre for Dermatology   (Canada)

^m Texas Dermatology Research Institute Dallas   (United States)

ⁿ UNIVERSITÉ CÔTE D'AZUR   (France)

^o UNIVERSITY OF WESTERN ONTARIO   (Canada)

^p UNIVERSITY OF MUNICH   (Germany)

^q OSLO UNIVERSITY HOSPITAL   (Norway)

^r GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t CEMIC   (Argentina)

^u RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^v UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^w NONE

more..

Author keywords

Alefacept; Biologicals; Efalizumab; Etanercept; Infliximab; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; CD4 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENILEUKIN DIFTITOX; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID ETHYL ESTER; HYDROXYUREA; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 4; METHOTREXATE; OKT 4; ONERCEPT; TUMOR NECROSIS FACTOR;

ALOPECIA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; DERMATOMYOSITIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EOSINOPHILIA; FATIGUE; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY; HYPERTENSION; IMMUNE DEFICIENCY; KIDNEY DISEASE; LEG ULCER; LIVER TOXICITY; LONG TERM CARE; LUNG FIBROSIS; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; SKIN MANIFESTATION; SYSTEMIC THERAPY; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 4544388284     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06070.x     Document Type: Conference Paper

References (106)

1. Prinz J. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 257-70.
2. de Arruda LH, De Moracs AP, The impact of psoriasis on quality of life. Br J Dermatol 2001; 144(Suppl. 58): 33-6.
3. Rapp SR. Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
4. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25: 1-10.
5. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998; 61: 11-21.
6. Boehncke WH. Immunomodulatory drugs for psoriasis. Br Med J 2003; 327: 634-5.
7. Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26: 362-7.
8. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40-6.
9. Griffiths CE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol 2003; 17(Suppl. 2): 1-5.
10. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents, J Am Acad Dermatol 2002; 46: 1-23.
11. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-10.
12. Gottlieb AB, Bos JD. Recombmantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105: 105-16.
13. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138: 657-63.
14. Kirby B, Griffiths CE. Novel immune-based therapies for psoriasis. Br J Dermatol 2002; 146: 546-51.
15. Dubertret L. Strategy for treatment of psoriasis: systemic treatments. J Dermatol 1998; 25: 788-92.
16. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
17. Salonen SH. The EUROPSO psoriasis patient study, treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Poster presented at the Spring Symposium of the European Academy of Dermatology and Venereology, 27 February-1 March 2003. Malta.
18. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120: 738-41.
19. Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
20. Spuls PI, Witkamp L, Bossuyt PM, et al. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-9.
21. Roenigk HH Jr. Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-85.
22. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464-75.
23. Finlay AY. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352-3.
24. Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999; 26: 723-33.
25. Menter MA, Abramovits W. Rational, sequential and combination regimens in the treatment of psoriasis. Dermatol Ther 1999; 11: 88-95.
26. Roenigk HH Jr. Combination and rotational therapy for psoriasis. In: Psoriasis (Hrah M, ed.). 3rd edn. New York: Marcel Dekker. 1998: 587-92.
27. 7 van de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001; 26: 356-61.
28. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-9.
29. Yamauchi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003; 49, S66-77.
30. Lampen A, Christians U, Bader A, et al. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 1996; 52: 159-68.
31. Li AP, Maurel P, Gornez-Lechon MJ, et al. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem Biol Interact 1997; 107: 5-16.
32. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45: 487-98.
33. Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low-dose cyclosporine: results of a multicenter placebo-controlled study. J Am Acad Dermatol 1994; 31: 68-74.
34. Paul BS, Momtaz K, Stern RS, et al. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7: 758-62.
35. Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA. etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177: 218-24.
36. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49: S57-61.
37. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-65.
38. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
39. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-27.
40. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13.
41. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
42. Gottlieb AB, Gordon KB, Caro I, et al. Long-term efalizumab therapy safely maintains psoriasis area and severity index improvement: preliminary results from an open-label trial. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004: Washington, DC. Poster 611.
43. Menter A, Cather JC. Long-term use of alefacept: safety and off-treatment responses in patients who have received multiple courses of therapy. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004: Washington, DC. Poster 608.
44. Gordon KB, Siegfried E, Carey W, et al. Impact of 24 weeks of continuous efalizumab therapy on patient-reported outcomes in patients with moderate to severe plaque psoriasis. Poster presented at the Meeting of the American Association of Dermatology Academy. 25-29 July 2003: Chicago, IL.
45. Genentech Inc. Raptiva™ (efauzumab). South San Francisco, CA: Genentech Inc., October 2003 (Package insert).
46. Cooper JC, Morgan G, Harding S, et al. Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells. Eur J Immunol 2003; 33: 666-75.
47. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003; 49: 816-25.
48. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infiximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
49. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56-61.
50. Vermeire S, Noman M, van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9.
51. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
52. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-9.
53. Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis. J Invest Dermatol 1990; 95: S49-52.
54. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.
55. Gelfand JM, Berlin J, van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425-9.
56. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
57. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
58. Wolfe F, Michaud K, Andersen J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9.
59. Gomez-Reino JJ, Cannona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
60. Moreland LW, Cohen SB, Baurngartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238-44.
61. Schaible TF. Long term safety of infliximab. Can J Gastroenterol 2000; 14(Suppl. C): C29-32.
62. Feldman SR, Bala M, Menter A, Gordon KB. The quality of life of patients with severe psoriasis treated with infliximab. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004: Washington, DC: Poster 7.
63. Papp KA, Miller B, Lynde C, et al. Efalizumab (anti-CD11a) retreatment; final results from an open-label study. Poster presented at the Meeting of the American Academy of Dermatology, 21-26 March 2003: San Francisco, CA.
64. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146: 118-21.
65. Krueger GG, van de Kerkhof P. Safety of multiple courses of alefacept in combination with other psoriasis therapies: a study that reflects the clinical practice setting. Poster presented at the 62nd Annual Meeting of the American Academy of Dermatology, 6-11 February 2004: Washington, DC. Poster 591.
66. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
67. Spuls PI, Bossuyt PM, van Everdingen JJ, et al. The development of practice guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol 1998; 134: 1591-6.
68. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49: 1-4.
69. Gach JE, Berth-Jones J. Successful treatment of recalcitrant psoriasis with a combination of infliximab and hydroxyurea. J Dermatol Treat 2003; 14: 226-8.
70. Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002; 47: 796-7.
71. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002; 41: 449-52.
72. Rongioletti F, Borenstein M, Kirsner R, et al. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat 2003; 14: 222-5.
73. Spuls PI, Hadi S, Rivera L, et al. Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatol Treat 2003; 14(Suppl. 2): 21-5.
74. Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 2003; 72: 396-8.
75. Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol 2003; 49: S78-86.
76. Walters IB, Burack LH, Coven TR, et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999; 40: 893-900.
77. Calzavara-Pinton PG, Carlino A, Manfredi E, et al. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol (Stockh) 1994; 186(Suppl.): 164-5.
78. Lauharanta J. Photochemotherapy. Clin Dermatol 1997; 15: 769-80.
79. Morison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134: 595-8.
80. Stem RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61.
81. ICN Pharmaceuticals Inc. Oxsoralen-Ultra® capsules (methoxsalen capsules, USP, 10 mg). Costa Mesa, CA: ICN Pharmaceuticals Inc., 1998 (package insert).
82. Novartis Pharmaceutical Corp. Neoral® soft gelatin capsules (cyclosporin capsules, USP) modified: Neoral® oral solution (cyclosporin oral solution, USP) modified. East Hanover, NJ: Novartis Pharmaceutical Corp., August 2002 (package insert).
83. De Rie MA, Bos JD. Cyclosporine immunotherapy. Clin Dermatol 1997; 15: 811-21.
84. Gawkrodger M. on behalf of the Therapy Guidelines and Audit Subcommittee of the British Association of Dermatologists. Current management of psoriasis. J Dermatol Treat 1997; 8: 27-55.
85. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204.
86. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623-9.
87. Lederle Pharmaceutical. Methotrexate sodium tablets, methotrexate sodium for injection, methotrexate LPF® sodium (methotrexate sodium injection) and methotrexate sodium injection. Pearl River, NY: Lederle Pharmaceutical, August 2001 (package insert).
88. Said S, Jeffes EW, Weinstein GD. Methotrexate. Clin Dermatol 1997; 15: 781-97.
89. Roche Laboratories Inc. Soriatane® (acitretin) capsules. Nutley, NJ: Roche Laboratories Inc., 1998 (Package insert).
90. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Furnaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: 424-9.
91. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with furnatic acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138: 456-60.
92. Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363-9.
93. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis, results and side effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
94. Biogen Inc. Amevive® (alefacept). Cambridge, MA: Biogen Inc., 2003 (Package insert).
95. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17(Suppl. 2): 12-6.
96. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003; 2: 624-8.
97. Ellis CN, Mordin NM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003; 4: 131-9.
98. Gordon KB, Papp KA, Hamilton TK, et al. Efalizuamb for patients with moderate to severe plaque psoriasis: a randomized controlled trial. J Am Med Assoc 2003; 290: 3073-80.
99. Immunex Corp. Enbrel® (etanercept). Thousand Oaks, CA: Immunex Corp., 2003 (Package insert).
100. Centocor Inc. Remicade® (infliximab). Malvern, PA: Centocor Inc., 2002 (Package insert).
101. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-35.
102. Gottlieb AB, Chaudhari U, Baker DG, et al. The National Psoriasis Foundation psoriasis score (NPF-PS) system versus the psoriasis area severity index (PASI) and physician's global assessment (PGA): a comparison. J Drugs Dermatol 2003; 3: 260-6.
103. Gottlieb AB, Psoriasis. Dis Manag Clin Outcomes 1998; 1: 195-202.
104. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithm-based approach for primary care physicians. Am Fam Physician 2000; 61: 725-33.
105. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-5.
106. Baughman RD, Sobel R. Psoriasis. A measure of severity. Arch Dermatol 1970; 101: 390-5.